SiranBio
苏州时安生物技术有限公司
Founded in May 2022 and headquartered in Suzhou Industrial Park, SiranBio develops innovative siRNA therapeutics.
Position in SVTR
Snapshot 2026-10-25- Startup SignalsTop 50%↓1
- Life SciencesTop 50%
About
Founded in May 2022 and headquartered in Suzhou Industrial Park, SiranBio develops innovative siRNA therapeutics. It has built three proprietary platforms: eSAFE chemical modification for off-target mitigation, the STORK-W single-molecule dual-target platform, and the STORK hepatic and extrahepatic targeted delivery platform, establishing a differentiated approach combining dual-target design with extrahepatic delivery. Its pipeline spans antiviral (chronic hepatitis B), metabolic and cardiovascular indications, led by SA1211, a dual-target siRNA aimed at functional cure of hepatitis B, and SA030, an ALK7-targeting candidate delivered systemically to adipose tissue. The company combines in-house pipeline development with out-licensing to multinational pharmaceutical companies.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 11
Investor· 10
Founders / team· 1
Funding history
- 2026-08-20Series A近4亿元人民币
Investors · BlueRun Ventures, 朗煜投资, 苏创投-天使母基金, 中启资本, IDG Capital, 阳光融汇资本, 国投招商, 华泰紫金, YuanBio Venture Capital, 苏州颢平Source · news.pedaily.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- SiranBio
Biotechnology
Series A · $139M · 2026-08
$139M
United States
BusinessLatest roundTotal raisedDate- Xaira Therapeutics
Integrated biotechnology applications involving artificial intelligence across the entire drug discovery and development process
Undisclosed · $1.0B · 2024-04
$1.0B - QbDVision
Digital CMC platform for pharma and biotech companies, streamlining drug development through structured workflows
Undisclosed · $13M · 2025-05
$13M - Pluto Bio
No-code tools that help pharma and biotech teams analyze and visualize complex biological data
Undisclosed · $4M · 2025-05
$4M
Europe
BusinessLatest roundTotal raisedDateOther / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in East China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 5 at a nearby stage · 4 in East China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in East China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in East China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 3 at a nearby stage · 6 in East China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 6 at a nearby stage · 4 in East China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.